Its pharmaceutical products include anesthetics, analgesics, antibiotics, ophthalmics, and hormones; and vaccine products comprise small animal, equine, and production animal biologicals."
On November 4, 2010, MWIV announced 4th quarter and fiscal year results for the period ended September 30, 2010. Revenues for the quarter came in at $358.9 million, up 45.0% over the prior year period. (The company which has been acquiring other entities broke out the growth as 19.2% organic and 25.8% related to the acquisition of Centaur Services).
Net income for the quarter was $8.8 million, up 34.3% over the same period the prior year. Diluted earnings per share were $.71 compared to $.53 the prior year.
In terms of guidance, the company estimated that in 2011, MWIV will have $1.41 to $1.46 billion in revenue representing a 15-19% growth, and that diluted earnings per share should come in between $3.02 - $3.10/share representing a 12-15% growth rate.
Examining Morningstar.com for longer-term results, we can see that revenues have grown from $606 million in 2006 to $1.2 billion in 2010. Similarly earnings per share have increased steadily from $1.25/share in 2006 to $2.70/share in 2010.
According to Morningstar, free cash flow has improved from a $(11) million level in 2006 to $12 million in 2007 before dipping to $7 million in 2008. Since 2008 free cash flow has improved and has been $12 million in the trailing twelve months (TTM).
Looking at the balance sheet, the company has $376 million in total current assets. Current liabilities stand at $212 million and total liabilities are reported at $221 million as of 9/10. With a current ratio of 1.77, and enough current assets to pay off ALL of the liabilities, the company appears to be in good condition at least based on the information we can glean from Morningstar.
In terms of valuatio, looking at the Yahoo "Key Statistics" on MWIV, we can see that this is a small cap stock with a market capitalization of only $788.41 million. The trailing p/e isn't too bad at 23.35 with a forward p/e (fye Sep 30, 2012) estimated at 18.15. Thus the PEG ratio, which I like to see between 1.0 and 1.5 comes in at 1.21 (5 yr expected).